Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

itioned for sustainable long-term growth," said Paul Bisaro, President and CEO. 

"On a proforma basis for the full-year 2012, we launched more than 1,000 generic products globally, and filed more than 1,500 applications globally.  Our Actavis Pharma pipeline is among the strongest in the industry with over 185 ANDAs on file with the U.S. FDA, including 49 first-to-file opportunities, of which, 33 represent potential exclusive first-to-files."

"In our Actavis Specialty Brands business, we experienced growth from U.S. sales of our key promoted products including Rapaflo®, Crinone®, and Generess® Fe.
We expanded our brand portfolio globally as we launched Rapaflo®, Gelnique®, Androderm® and Oxytrol® in Canada and prepared for launches of key branded products in Latin America.  We continued to record progress in our biosimilar initiatives as we acquired a biosimilar to Herceptin® from Synthon and contributed the product to the Amgen collaboration which includes Herceptin®, Avastin®, Rituxan/MabThera® and Erbitux®. Additionally, rFSH entered into the Phase I clinical program."

In January 2013, we acquired Uteron Pharma SA which adds three near term and three longer term projects to our Women's Health development portfolio," Bisaro continued.

"In 2012, we continued to utilize our strong balance sheet as we issued $3.9 billion in senior unsecured notes and completed a new $1.8 billion term loan facility at favorable rates.  We are focused on repaying our debt and maintaining a strong financial foundation to support strategic growth initiatives within our global businesses," concluded Bisaro. 

Fourth Quarter and Full Year 2012 Business Segment ResultsActavis Pharma Segment InformationThree Months EndedTwelve Months Ende
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... announced that Phil Hagerman , Chairman & CEO, and ... investor conferences. Mr. Hagerman and Mr. Whelan ... Conference in Boston on Wednesday, September ... and Mr. Whelan are also scheduled to participate in the ...
(Date:8/31/2015)...  AMRI (NASDAQ: AMRI ) and Saneca ... on the development, manufacture and marketing of a ... collaboration combines Saneca,s strength in extracting opiates from ... manufacturing controlled substance APIs with AMRI,s U.S. assets ... these facilities. The collaboration will also capitalize on ...
(Date:8/31/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical ... therapeutics for the treatment of diseases of the central ... BNC101 IND submission has passed review by the US ... a Phase 1 clinical trial in patients with metastatic ... prior to 31 December 2015. Bionomics, CEO ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... Jan. 26, 2011 QPS, LLC, a leading full-service ... preclinical and clinical research and development, announced the acquisition ... a full service phase 1 CRO headquartered in Hyderabad, ... QPS is a global CRO supporting drug discovery and ...
... FORT WORTH, Texas, Jan. 26, 2011 Wound Management ... an emerging leader in advanced wound care solutions, announced ... provider, Secure eHealth will be included in a technology ... Conference February 21st-24th at the Orange County Convention Center ...
Cached Medicine Technology:QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, India 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 3Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 4
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) just announced ... figures who are finding joint pain relief after using their revolutionary Micro-Impact Platform™ . ... in the world said, “For the first time in over 20 years I am ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health ... "make at least half your grains whole,” with the majority of Americans eating more ... Whole Grains Council (WGC) released these findings and others from the 2015 Whole ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, July 11, 2015, during ... in New York City, NYSATA was proud to recognize Dr. Merritt F. Spear as ... Recognition Award, named after long-time NYSATA member and Ithaca College athletic trainer and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... All birth ... has one of the lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy ... Still, some men hesitate to have their vasectomy done because they are afraid of ...
Breaking Medicine News(10 mins):Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 2Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2
... SILVER SPRING, Md., July 6 The Obesity Society, the ... obesity, is pleased to announce the selection of Francesca M. ... Ms. Dea comes to The Obesity Society with an ... and media relations. , , According to Robert Kushner, ...
... famotidine effective at curtailing ulcers , MONDAY, July 6 (HealthDay ... in people taking low-dose aspirin, often to reduce the risk ... phase III trial included 404 patients taking 75 milligrams to ... to take either 20 milligrams of famotidine or a placebo ...
... in those with advanced chronic heart failure, have an ... to new research from researchers at the University of ... in the European Heart Journal , also suggest ... risk of death in heart failure patients, contradicting previous ...
... 6 SCAN Health Plan of Arizona has announced that ... Studios today. This partnership allows SCAN Health Plan to regularly ... and weekend shows. , , SCAN also will serve ... Gila River Casino Club 55+. This initiative is part of ...
... future of organ transplantation could include microscopic beads that ... new organ, Medical College of Georgia researchers say. ... at the MCG Center for Molecular Chaperone/Radiobiology and Cancer ... with skin grafts. The degradable microparticles deliver the ...
... Blood Types - Patients Need YOU , , NEW ... York Blood Center (NYBC) and its divisions in Manhattan, Long ... call upon the community to please give blood this month. ... of all blood types and ethnicities are encouraged to donate ...
Cached Medicine News:Health News:The Obesity Society Selects Executive Vice President 2Health News:Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin 2Health News:Atrial fibrillation linked to increased hospitalization in heart failure patients 2Health News:Arizona's AM 1230 KOY to be Broadcast from SCAN Health Plan Studios 2Health News:Microscopic 'beads' could help create 'designer' immune cells that ignore transplanted organs 2Health News:Who Says Negatives Can't Be Positive? 2Health News:Who Says Negatives Can't Be Positive? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: